Ticker
URGNCompany Name
UROGEN PHARMA LTDSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Total Assets | Cash and Equivalents | Cash to Assets Ratio |
---|---|---|---|
6/30/2025 | $ 208.72M | $ 93.99M | 45.03% |
3/31/2025 | $ 247.62M | $ 105.11M | 42.45% |
12/31/2024 | $ 285.71M | $ 173.06M | 60.57% |
9/30/2024 | $ 301.94M | $ 125.99M | 41.73% |
6/30/2024 | $ 281.85M | $ 220.8M | 78.34% |
3/31/2024 | $ 200.57M | $ 132.26M | 65.94% |
12/31/2023 | $ 178.31M | $ 95.82M | 53.74% |
9/30/2023 | $ 193.63M | $ 120.12M | 62.04% |
6/30/2023 | $ 95.36M | $ 20.94M | 21.96% |
3/31/2023 | $ 112.95M | $ 37.35M | 33.07% |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for UROGEN PHARMA LTD is calculated as follows: CashnEq [ $ 25.79M ] / Assets [ $ 139.89M ]
(=) Cash to Assets [ 18.43% ]
Minimum
Sep 30, 2020
Maximum
Jun 30, 2024
Average
Median
filtered constituents | 3.95K |
---|---|
min | 0% |
max | 40.92% |
average | 9.84% |
median | 6.44% |
std | 9.62% |